Genera’s low false negatives
Wednesday, 15 October, 2008
Pilot clinical trials of Genera Biosystems' [ASX: GBI] new PapType HPV detection test have shown that the test gives improved detection rates of cervical cancer than the market leader test.
Currently Qiagen's Hybrid Capture 2 test (HC2) is the only FDA-approved test for cervical cancer screening.
But in Genera's latest trials, PapType outperformed the HC2 test, returning a false negative rate of seven per cent, compared to a 27 per cent false negative rate with HC2.
Genera believes the results are very encouraging, although they are not yet conclusive.
For example, all the women in the study already had an abnormal pap smear. According to Genera, trials from the general population will need to be conducted before the superiority of PapType can be confirmed.
Potential biological targets for vascular dementia
Caused by damage to blood vessels in the brain, there is currently no approved treatment for...
Ecopha Biotech announces strategic cross-border model
To commercialise its ecopha.bio technology for a Pongamia-based bioeconomy, Australian company...
Could this 'virus-tearing' plastic film protect hospital equipment?
A thin plastic film that tears apart viruses on contact could help protect high-touch hospital...
